药物洗脱支架在经皮冠状动脉介入治疗中的应用现状

doi:10.3969/j.issn.2095-378X.2021.03.014

外科研究与新技术 ›› 2021, Vol. 10 ›› Issue (3): 209-213.doi: 10.3969/j.issn.2095-378X.2021.03.014

药物洗脱支架在经皮冠状动脉介入治疗中的应用现状

刘朋综述, 于玲莉审校

上海药品审评核查中心化学药品审评核查部,上海 201203

收稿日期:2021-08-11 出版日期:2021-09-28 发布日期:2022-08-22
通讯作者: 于玲莉,电子信箱：yulingli@smda.sh.cn
作者简介:刘朋（1982—）,女,博士,中级工程师,从事药品监管科学

Current application of percutaneous coronary intervention with drug-eluting stents

LIU Peng, YU Lingli

Department of Chemical Substance, Shanghai Center for Drug Evaluation and Inspection, Shanghai 201203, China

Received:2021-08-11 Online:2021-09-28 Published:2022-08-22

摘要/Abstract

摘要： 对于动脉粥样硬化导致的血管狭窄等血管疾病而言,经皮冠状动脉介入结合血管支架植入是一种最有效、最微创的治疗方法。为不断改善血管支架在临床使用过程中存在的问题,如：再狭窄、支架内血栓等,不同种类的支架被开发并获批上市。药物洗脱支架整合了传统金属支架和抗增殖药物治疗的双重优势,显著降低了支架内再狭窄和血运重建发生率。本文汇总了国内外现有药物洗脱支架的载药类型、临床安全性、有效性、发展现状及研究进展,以期加深临床医师、科研人员及患者对药物洗脱支架的认识,为临床使用中更好地防控风险、作出合理的选择提供帮助。

关键词: 药物洗脱支架, 冠状动脉疾病, 支架内血栓, 再狭窄, 生物可降解聚合物

Abstract: Percutaneous coronary intervention combined with drug-eluting stents （DES） implantation has been recognized as the most effective and minimally invasive method for treating vascular diseases such as vascular stenosis caused by atherosclerosis. In order to resolve the problems existing in the clinical use of vascular stents, such as restenosis and in-stent thrombosis, various types of stents have been developed and approved to enter the market. DES integrate the dual advantages of traditional metal stents and antiproliferative drugs, and significantly reduce the incidence of in-stent restenosis and revascularization. This review summarized research progress on the drug loading, safety, and effectiveness of DES, aiming to improve the understanding of DES among clinicians, researchers, and patients and to better control related risks and make reasonable choices in clinical practice.

Key words: Drug-eluting stent, Coronary artery disease, In-stent restenosis, Restenosis, Biodegradable polymer

中图分类号:

R608

刘朋, 于玲莉. 药物洗脱支架在经皮冠状动脉介入治疗中的应用现状[J]. 外科研究与新技术, 2021, 10(3): 209-213.

LIU Peng, YU Lingli. Current application of percutaneous coronary intervention with drug-eluting stents[J]. Surgical Research and New Technique, 2021, 10(3): 209-213.

参考文献

[1] Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study2013[J]. Lancet, 2015,385(9963):117-171.
[2] 《中国心血管健康与疾病报告》编写组.《中国心血管健康与疾病报告2020》概述[J].中国心血管病研究, 2021.19(7): 582-590.
[3] Malakar A K, Choudhury D, Halder B, et al.A review on coronary artery disease, its risk factors, and therapeutics[J]. J Cell Physiol, 2019,234(10):16812-16823.
[4] 心血管植入物血管内器械第2部分:血管支架[S]. 中华人民共和国医药行业标准,YY/T 0663,2-2016.
[5] Song J, Kouidri S, Bakir F.Review on the numerical investigations of mass transfer from drug eluting stent[J]. Biocybern Biomed Eng, 2021,41(3):1057-1070.
[6] Sotomi Y, Onuma Y, Collet C, et al.Bioresorbable scaffold the emerging reality and future directions[J]. Circ Res, 2017,120(8):1341-1352.
[7] Buccheri D, Piraino D, Andolina G,et al.Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment[J]. J Thorac Dis, 2016,8(10):1150-1152.
[8] Tanaka A, Jabbour R J, Mitomo S, et al.Hybrid percutaneous coronary intervention with bioresorbable vascular scaffolds in combination with drug-eluting stents or drug-coated balloons for complex coronary lesions[J]. JACC Cardiovasc Interv, 2017,10(6):539-547.
[9] Sousa J E, Costa M A, Abizaid A, et al.Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study[J]. Circulation, 2001,103(2):192-195.
[10] 国家食品药品监督管理总局医疗器械技术审评中心.冠状动脉药物洗脱支架临床试验指导原则[EB](2018年第21号).
[11] Kirtane AJ, Gupta A, Iyengar S, et al.Safety and efficacy of drug-eluting and bare metal stents comprehensive meta-analysis of randomized trials and observational studies[J]. Circulation, 2009,119(25),3198-3206.
[12] Raber L, Magro M, Stefanini GG, et al.Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study[J]. Circulation, 2012,125(9):1110-1121.
[13] Tada T, Byrne RA, Simunovic I, et al.Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents results from a registry of 18,334 patients[J]. JACC Cardiovasc Interv, 2013,6(12):1267-1274.
[14] Moreno R, Fernández C, Hernández R, et al.Drug-eluting stent thrombosis results from a pooled analysis including 10 randomized studies[J].J Am Coll Cardiol,2005,45(6): 954-959.
[15] Joner M, Finn AV, Farb A, et al.Pathology of drug-eluting stents in humans delayed healing and late thrombotic risk[J]. J Am Coll Cardiol, 2006,48(1): 193-202.
[16] Virmani R, Giulio G, Farb A, et al.Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious?[J].Circulation 2004,109(6):701-705.
[17] Levine GN, Bates ER, Bittl JA, et al.ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelies[J]. Circulation, 2016,134(10):123-155.
[18] McQueen A, Escuer J, Aggarwal A, et al. Do we really understand how drug eluted from stents modulates arterial healing?[J]. Int J Pharm, 2021,601(2):120575-120575.
[19] Nogic J, McCormick LM, Francis R, et al. Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents[J]. J Cardiol, 2018,71(5): 435-443.
[20] Serruys PW, Farooq V, Kalesan B, et al.Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) Randomized, Noninferiority Trial[J]. JACC: Cardiovasc Interv, 2013,6(8):777-789.
[21] Chen W, Habraken TCJ, Hennink WE, et al.Polymer-free drug-eluting stents: an overview of coating strategies and comparison with polymer-coated drug-eluting stents[J]. Bioconjug Chem,2015,26(7):1277-1288.
[22] Urban P, Meredith IT, Abizaid A, et al.Polymer-free drug-coated coronary stents in patients at high bleeding risk[J]. New Eng J med, 2015,373(21):2038-2047.
[23] Maes F, Costerousse O, Cieza T, et al.Transradial experience with bioresorbable vascular scaffolds: a case-matched study with metallic drug-eluting stents[J].Cardiovasc Revasc Med, 2018,19(6):700-704.
[24] 周生刚,游远琪,徐阳,等.生物可降解金属基支架的应用进展[J]. 昆明理工大学学报(自然科学版),2021,3(46):18-26.
[25] 王洋洋,吴红枚,甄文强,等.生物可降解血管支架研究进展[J].中国医疗器械杂志,2021,45(4):410-415.
[26] Serruys PW, Garcia-Garcia HM, Onuma Y.From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?[J]. Eur Heart J,2012,33(1):16-25.
[27] Karanasiou GS, Papafaklis MI, Conway C, et al.Stents: biomechanics, biomaterials, and insights from computational modeling[J]. Ann Biomed Eng, 2017,45(4):853-872.
[28] Cassese S, Byrne RA, Ndrepepa G, et al.Everolimus-eluting bioresorbable vascular scaff olds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials[J]. Lancet,2016,387(10018):537-544.

药物洗脱支架在经皮冠状动脉介入治疗中的应用现状

Current application of percutaneous coronary intervention with drug-eluting stents

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价